Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Ruxolitinib discontinuation syndrome: real-world data

Francesca Palandri, PhD, MD, of the University Hospital, Bologna, Italy, discusses real-world data on the incidence of ruxolitinib discontinuation syndrome in myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).